| The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection M Rudwaleit, D Van Der Heijde, R Landewé, J Listing, N Akkoc, J Brandt, ... Annals of the rheumatic diseases 68 (6), 777-783, 2009 | 4489 | 2009 |
| The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general M Rudwaleit, D van der Heijde, R Landewé, N Akkoc, J Brandt, CT Chou, ... Annals of the rheumatic diseases 70 (1), 25-31, 2011 | 1925 | 2011 |
| Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force JS Smolen, J Braun, M Dougados, P Emery, O FitzGerald, P Helliwell, ... Annals of the rheumatic diseases 73 (1), 6-16, 2014 | 614 | 2014 |
| Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study D van der Heijde, A Deodhar, JC Wei, E Drescher, D Fleishaker, ... Annals of the rheumatic diseases 76 (8), 1340-1347, 2017 | 361 | 2017 |
| Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological … D van der Heijde, JCC Wei, M Dougados, P Mease, A Deodhar, ... The Lancet 392 (10163), 2441-2451, 2018 | 351 | 2018 |
| Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study D Baeten, M Østergaard, JCC Wei, J Sieper, P Järvinen, LS Tam, ... Annals of the rheumatic diseases 77 (9), 1295-1302, 2018 | 336 | 2018 |
| Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double‐blind … M Dougados, D van der Heijde, J Sieper, J Braun, WP Maksymowych, ... Arthritis & rheumatology 66 (8), 2091-2102, 2014 | 248 | 2014 |
| Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks W Wang, CY Wang, SI Wang, JCC Wei EClinicalMedicine 53, 2022 | 173 | 2022 |
| Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan KH Yu, DY Chen, JH Chen, SY Chen, SM Chen, TT Cheng, SC Hsieh, ... International journal of rheumatic diseases 21 (4), 772-787, 2018 | 135 | 2018 |
| Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis U Kiltz, D Van Der Heijde, A Boonen, N Akkoc, W Bautista-Molano, ... Annals of the rheumatic diseases 77 (9), 1311-1317, 2018 | 129 | 2018 |
| Epigallocatechin gallate attenuates amyloid β-induced inflammation and neurotoxicity in EOC 13.31 microglia JCC Wei, HC Huang, WJ Chen, CN Huang, CH Peng, CL Lin European journal of pharmacology 770, 16-24, 2016 | 122 | 2016 |
| Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo … Y Tanaka, T Takeuchi, S Tanaka, A Kawakami, M Iwasaki, YW Song, ... Annals of the rheumatic diseases 78 (10), 1320-1332, 2019 | 111 | 2019 |
| Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 … X Baraliakos, AJ Kivitz, AA Deodhar, J Braun, JC Wei, EM Delicha, ... Clin Exp Rheumatol 36 (1), 50-55, 2018 | 106 | 2018 |
| Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese CT Chou, AE Timms, JCC Wei, WC Tsai, BP Wordsworth, MA Brown Annals of the rheumatic diseases 65 (8), 1106-1109, 2006 | 97 | 2006 |
| Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up EL Kneepkens, JCC Wei, MT Nurmohamed, KJ Yeo, CY Chen, ... Annals of the rheumatic diseases 74 (2), 396-401, 2015 | 96 | 2015 |
| Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis A Sepriano, R Landewé, D van der Heijde, J Sieper, N Akkoc, J Brandt, ... Annals of the rheumatic diseases 75 (6), 1034-1042, 2016 | 93 | 2016 |
| Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. JCC Wei, TW Chan, HS Lin, F Huang, CT Chou The Journal of rheumatology 30 (12), 2627-2631, 2003 | 91 | 2003 |
| Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V … M Dougados, JCC Wei, R Landewé, J Sieper, X Baraliakos, ... Annals of the rheumatic diseases 79 (2), 176-185, 2020 | 90 | 2020 |
| Association between hyperuricemia and metabolic syndrome: an epidemiological study of a labor force population in Taiwan CY Wei, CC Sun, JCC Wei, HC Tai, CA Sun, CF Chung, YC Chou, PL Lin, ... BioMed research international 2015, 2015 | 80 | 2015 |
| Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial T Takeuchi, Y Tanaka, H Yamanaka, K Amano, R Nagamine, W Park, ... Modern rheumatology 26 (1), 15-23, 2016 | 77 | 2016 |
Jeng Yuan ChiouChung Shan Medical University在 csmu.edu.tw 的電子郵件地址已通過驗證
